Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Gynecologic 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Metastatic 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 123Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67abiraterone 51atezolizumab 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39darolutamide 39Sorafenib 39apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Abituzumab × Genitourinary × Clear all
NCT00958477 2017-08-02

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled 44 charts
Genitourinary

Prostatic Neoplasms

NCT01360840 2015-12-14

PERSEUS

EMD Serono

Phase 2 Completed
180 enrolled 23 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡